Stanford Scientists Discover “Natural Ozempic” Without Side Effects

Why It Matters

BRP could offer a more targeted, side‑effect‑free obesity therapy, addressing a market where effective drugs remain scarce. Its success would validate AI‑driven peptide discovery as a fast track for metabolic‑disorder treatments.

Key Takeaways

• Stanford team discovered peptide BRP that cuts appetite in animals.
• BRP reduces food intake up to 50% without nausea or constipation.
• AI-driven Peptide Predictor screened 20,000 genes to find BRP candidate.
• Early animal trials show fat loss and improved glucose tolerance.
• Merrifield Therapeutics aims to start human trials for BRP soon.

Pulse Analysis

Obesity remains a leading driver of chronic disease, and the market has been dominated by GLP‑1 analogues such as semaglutide, which, while effective, bring gastrointestinal side effects that limit patient adherence. The Stanford team’s BRP peptide sidesteps these issues by acting primarily in the hypothalamus, the brain’s appetite hub, rather than the gut‑pancreas axis. This refined mechanism promises comparable weight‑loss outcomes with a cleaner safety profile, a combination that could reshape prescribing patterns for endocrinologists and primary‑care physicians alike.

The breakthrough was powered by an AI platform named Peptide Predictor, which parsed the human proteome to identify prohormone fragments with hormone‑like activity. By focusing on secreted proteins and leveraging the enzyme prohormone convertase 1/3 as a biological filter, the algorithm narrowed 20,000 genes to 373 candidates, ultimately spotlighting the 12‑residue BRP. This approach demonstrates how machine learning can accelerate drug discovery, reducing years of trial‑and‑error lab work to months of computational screening, and may become a template for future peptide‑based therapeutics.

Commercially, BRP’s entry into human trials could ignite a new wave of biotech investment focused on AI‑derived biologics. If efficacy and tolerability are confirmed, Merrifield Therapeutics could capture a sizable share of the projected $70 billion global obesity‑treatment market. Moreover, the technology’s adaptability suggests potential extensions into diabetes, metabolic syndrome, and even neuro‑psychiatric conditions linked to appetite regulation. Regulators will likely scrutinize the novel mechanism, but the precedent set by GLP‑1 drugs may smooth the pathway, positioning BRP as a next‑generation, precision‑focused weight‑loss solution.